Achieve Life Sciences (ACHV) vs Oruka Therapeutics (ORKA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Achieve Life Sciences (ACHV) over the past year, gaining 241.6% versus a gain of 108.4%. Over five years, ORKA leads with a +130.8% price change compared with -10.7% for ACHV. Oruka Therapeutics is the larger company by market cap ($5.12 billion vs $741.3 million), about 6.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | ORKA |
|---|---|---|
| Share price | $7.19 | $77.28 |
| Market cap | $741.31M | $5.12B |
| 1-day change | -0.69% | -2.79% |
| YTD return | +44.67% | +154.97% |
| 1-year return | +108.41% | +241.64% |
| 5-year return | -10.68% | +130.82% |
| EPS (TTM) | $-1.69 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-105.43M |
| 52-week high | $8.64 | $115.52 |
| 52-week low | $2.62 | $24.31 |
| Distance from 52-week high | -16.78% | -33.10% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +96.80% | +100.57% |
| Average volume | 1.43M | 896.59K |
| Shares outstanding | 103.10M | 66.21M |
| Employees | 28 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 6.9 times larger than Achieve Life Sciences by market value ($5.12B vs $741.31M).
- ORKA has outperformed ACHV by 133.2 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
ACHV vs ORKA FAQ
Which is bigger, Achieve Life Sciences or Oruka Therapeutics?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.12B compared with $741.31M for Achieve Life Sciences (ACHV).
Which stock has performed better over the past year, ACHV or ORKA?
ORKA returned +241.64% over the past 12 months, compared with +108.41% for ACHV (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Oruka Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.